Emerging research within the field of personalised medicines has aimed to enhance patient treatment through the use of pharmaceutical products that are customised to the individual needs and preferences of the patient. The currently dominant production platforms of pharmaceutical products, however, regard a mass production paradigm and are thus unfeasible for the production and provision of personalised medicines. The production platforms are not designed or are intended for a customisation context. Operating such a context with the current supply chain entails challenges such as increasing costs, time to patient and efforts in quality assurance activities. To address these challenges, this paper presents four reconfigured pharmaceutical supply chain designs. A qualitative operational performance assessment elicits the strengths and weaknesses of the respective supply chain design operating in a customisation context. The results suggest that a later point of variegation, that is, the point in the supply chain where the final customisation is achieved, can relieve the operational effort of the stakeholders in the supply chain while providing the benefits of personalised medicines, that is, an enhanced treatment outcome of the patient. A trade-off remains, however, between the supply chain’s decreased operational effort and degree of necessary reconfigurations, such as introducing new functions to stakeholder operation, reallocating activities to other stakeholders or educating stakeholders.

个性化药物领域内的新兴研究旨在通过使用针对患者个人需求和喜好定制的药品来提高患者治疗水平。但是，当前占主导地位的药品生产平台考虑了大规模生产的范式，因此对于个性化药品的生产和提供是不可行的。生产平台不是经过设计的，也不打算用于自定义环境。在当前的供应链中运作这种情况带来了挑战，例如成本增加，患者等待时间增加以及质量保证活动的努力。为了应对这些挑战，本文提出了四种重新配置的药品供应链设计。定性的运营绩效评估得出了在定制环境中运营的各个供应链设计的优缺点。结果表明，稍后的多样化点，即实现最终定制的供应链点，可以减轻供应链中利益相关者的操作工作，同时提供个性化药品的好处，即增强了患者的治疗效果。但是，在供应链减少的运营工作量和必要的重新配置程度之间仍然需要权衡取舍，例如为利益相关者运营引入新功能，将活动重新分配给其他利益相关者或教育利益相关者。结果表明，稍后的多样化点，即实现最终定制的供应链点，可以减轻供应链中利益相关者的操作工作，同时提供个性化药品的好处，即增强了患者的治疗效果。但是，在供应链减少的工作量和必要的重新配置程度之间仍然需要权衡取舍，例如将新功能引入利益相关者运作，将活动重新分配给其他利益相关者或教育利益相关者。结果表明，稍后的多样化点，即实现最终定制的供应链点，可以减轻供应链中利益相关者的操作工作，同时提供个性化药品的好处，即增强了患者的治疗效果。但是，在供应链减少的运营工作量和必要的重新配置程度之间仍然需要权衡取舍，例如为利益相关者运营引入新功能，将活动重新分配给其他利益相关者或教育利益相关者。增强了患者的治疗效果。但是，在供应链减少的运营工作量和必要的重新配置程度之间仍然需要权衡取舍，例如为利益相关者运营引入新功能，将活动重新分配给其他利益相关者或教育利益相关者。增强了患者的治疗效果。但是，在供应链减少的运营工作量和必要的重新配置程度之间仍然需要权衡取舍，例如为利益相关者运营引入新功能，将活动重新分配给其他利益相关者或教育利益相关者。